Uplarafenib

Research use only, not for human use.

Uplarafenib (B-Raf IN 10) is a potent BRAF inhibitor with an IC50 of 50-100 nM. B-Raf IN 10 exhibits antitumor activity that may influence cell proliferation and differentiation, making it suitable for studying solid tumors.

Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. Uplarafenib shows antitumor activity.

Uplarafenib (Compound C09) (1 μM) shows more than 89% inhibition against BRAF and BRAF V600E.Uplarafenib shows an IC50 between 50 and 100 nM against BRAF, less than 50 nM against BRAF V600E.Uplarafenib (72 h) inhibits A375 and SK-MEL-28 cells growth but not CHL-1 and SK-MEL-31 cells.Cell Viability Assay Cell Line:A375, SK-MEL-28, SK-MEL-31 and CHL-1 Concentration:Incubation Time:72 h Result:Showed inhibition with IC50s less than 500 nM against A375 and SK-MEL-28 cells, and showed no inhibition against CHL-1 and SK-MEL-31.

——

——

MAPK/ERK Signaling

Raf

Raf

——

——

1425485-87-5

494.49

C22H21F3N4O4S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (202.23 mM; Ultrasonic (<60°C)

CCCS(=O)(=O)Nc1cc(F)c(F)c(C(=O)c2ccc3ncc(nc3c2)N2CCOCC2)c1F

——

(-20℃)

With Ice Pack

≥ 2 years